Product Description
A plasmid DNA encoding the A chain of the diphtheria toxin (DT-A) driven by the transcriptional regulatory sequences of human H19, with potential antineoplastic activity. Because the expression of DT-A is under the control of H19 promotor elements, DT-A is selectively expressed in tumor cells capable of turning on H-19.
Mechanisms of Action: ADPr Catalyzer
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ChemomAb
Company Location: TEL AVIV L3 6158002
Company CEO: Dale Pfost
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Diphtheria|Bladder Cancer|Transitional Cell Carcinoma|Carcinoma in Situ|Pancreatic Cancer|Ovarian Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| BC-07-01.CTIL | P2 |
Completed |
Bladder Cancer |
2013-01-01 |
2019-05-01 |
Study Completion Date|Treatments|Trial Status |
|
| BC-08-01 | P2 |
Completed |
Ovarian Cancer |
2012-02-01 |
2019-06-14 |
Primary Completion Date|Study Completion Date|Treatments |
|
| BC-07-05 | P2 |
Completed |
Pancreatic Cancer |
2010-10-01 |
2019-03-22 |
Treatments |
|
| BC-05-02.CTIL | P2 |
Completed |
Transitional Cell Carcinoma|Carcinoma in Situ|Bladder Cancer|Diphtheria |
2007-11-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|